Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix has provided a corporate update, highlighting significant advancements with NBTXR3 for treating head and neck cancer. The first European patient has been randomized in the pivotal NANORAY-312 study, with U.S. and Asia site activations expected to follow. The company aims to establish a registration pathway for NBTXR3 in combination with anti-PD-1 therapy based on positive initial data from ongoing studies. Financially, Nanobiotix has extended its operating runway into Q2 2023 through improved operational efficiencies and capital optimization.
Nanobiotix announced the first patient enrollment in the pivotal NANORAY-312 phase III study assessing radiotherapy-activated NBTXR3, with or without cetuximab, for elderly patients with locally advanced head and neck squamous cell carcinoma. This study aims to prove the superiority of NBTXR3 over standard treatments. The US FDA has granted Fast Track designation for NBTXR3 in this patient group, allowing for faster review and potential accelerated approval.
Nanobiotix, a late-stage clinical biotechnology company, announced participation in three virtual investor conferences in January 2022. The events include:
- Oddo BHF Forum 2022: January 6-11, 2022
- H.C. Wainwright Bioconnect Conference: January 10-13, 2022
- Biotech Showcase™ 2022: January 17-19, 2022
Nanobiotix has reported its voting rights and share count as of November 30, 2021. The company has 34,825,872 shares outstanding, with a total of 36,003,389 voting rights (gross) and 35,985,166 voting rights (net). This information aligns with regulatory requirements set by the French Financial Markets Authority.
Nanobiotix, listed on both Euronext Paris and Nasdaq, specializes in innovative therapeutic approaches in biotechnology, focusing on oncology and has market authorization for its lead candidate, NBTXR3.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company focusing on innovative cancer treatments, announced participation by CEO Laurent Levy in a virtual fireside chat at the Evercore ISI HealthCONx Conference on December 2, 2021, at 1:00 PM EST. The live audio webcast will be accessible on the company’s website, with an archived recording available for 90 days. NANOBIOTIX, founded in 2003 and headquartered in Paris, is known for its physics-based therapeutic approaches and has market authorization for its product NBTXR3 in Europe.
NBTXR3, developed by Nanobiotix, shows promising preclinical results presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC). The data indicate that radiotherapy-activated NBTXR3 enhances CD8+ T cell infiltration and modulates the T cell receptor repertoire, suggesting improved immune priming. Additionally, the combination of NBTXR3 with anti-PD-1, anti-LAG3, and anti-TIGIT substantially elevated anti-tumor immune response activities. These findings underscore potential advancements in combination therapies for solid tumors.
Nanobiotix announced its latest regulatory update as of October 31, 2021, reporting a total of 34,825,872 shares outstanding. The gross total number of voting rights is 36,003,389, while the net total is 35,983,625. This update is in compliance with the French Commercial Code and aims to ensure transparency in shareholder communications. Established in 2003, the company focuses on innovative therapeutic solutions in oncology, with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma.
Nanobiotix, a late-stage biotechnology company specializing in innovative cancer treatments, announced CEO Laurent Levy's participation in a fireside chat at the Jefferies London Healthcare Conference. Scheduled for November 16, 2021, at 3:40 PM GMT/10:40 AM EST, the event will be live-streamed on the company's website. Established in 2003, Nanobiotix focuses on physics-based therapies and holds over 30 patents. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand name Hensify®.
Nanobiotix has released first survival data from its NBTXR3 program at the ASTRO 2021 Annual Meeting. In a group of 41 elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the median overall survival (mOS) was 18.1 months and median progression-free survival (mPFS) was 10.6 months. The best objective response rate (ORR) was 85.4%, with a complete response rate (CRR) of 63.4%. These positive findings support future phase III trials aimed at this challenging patient group.
Nanobiotix (NASDAQ: NBTX) reported progress in its oncology clinical programs, highlighting published preclinical data in the Red Journal about NBTXR3 combined with radiotherapy and anti-PD-1. The company is set to present survival data from its head and neck cancer program at the ASTRO meeting from October 24-27, 2021. As of September 30, 2021, Nanobiotix had €89.8 million in cash. It is on track to activate clinical trial sites for its pivotal phase III study, NANORAY-312, in the coming weeks.